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NICEObjective. There are widespread efforts to increase symptom awareness of ‘pelvic/abdominal pain, increased
abdominal size/bloating, difficulty eating/feeling full and urinary frequency/urgency’ in an attempt to diagnose
ovarian cancer earlier. Long-term survival ofwomenwith these symptoms adjusted for knownprognostic factors
is yet to be determined. This study explored the association of symptoms, routes and interval to diagnosis and
long-term survival in a population-based cohort of postmenopausal women diagnosed with invasive epithelial
tubo-ovarian cancer (iEOC) in the ‘no screen’ (control) UKCTOCS arm.
Methods. Of 101,299 women in the control arm, 574 were confirmed on outcome review to have iEOC be-
tween randomisation (2001–2005) and 31 December 2014. Data was extracted from medical notes and elec-
tronic records. A multivariable model was fitted for individual symptoms, time interval from symptom onset
to diagnosis, route to diagnosis, speciality,morphological Type, age at diagnosis, year of diagnosis (period effect),
stage, primary treatment, and residual disease.
Results. Women presenting with symptoms listed in the NICE guidelines (HR1.48, 95%CI1.16–1.89, p =
0.001) or the modified Goff Index (HR1·68, 95%CI1·32–2.13, p b 0.0001) had significantly worse survival than
those who did not. Each additional presenting symptom decreased survival (HR1·20, 95%CI1·12–1·28,
p b 0.0001). In multivariable analysis, in addition to advanced stage, increasing residual disease and inadequate
primary treatment, abdominal pain and loss of appetite/feeling full were significantly associated with increased
mortality.CL, 2nd Floor, Institute of Clinical Trials & Methodology, University College London, London WC1V 6LJ, UK.
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cohort study in the ‘no scree..., GynecologicConclusions. The ovarian cancer symptom indices identify postmenopausal women with a poorer prognosis.
This study however cannot exclude the possibility of better outcomes in those who are aware and act on their
symptoms.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ovarian cancer continues to be diagnosed at advanced stage with
high fatality rates. A significant contributing factor is lack of clear
alarm symptoms. To address this, substantial work in exploring
symptoms has been undertaken. Although symptoms in women di-
agnosed with early and late stage disease were described as early
as 1985 [1], it was Goff et al. [2,3] in 2004 who gave impetus to this
effort by describing a symptom triad (pelvic/abdominal pain, in-
creased abdominal size/bloating and difficulty eating/feeling full)
frequently associated with ovarian cancer. This Goff Index [3] with
some modifications [4,5] has since been widely used across the
globe to drive awareness campaigns [6] among the public and pri-
mary care physicians.
Testing symptomatic women was studied in the DOvE randomised
controlled trial [7]. Although there was no stage shift, there was a
trend to higher complete tumour resection rates in women diagnosed
with ovarian cancer in the intervention compared to the standard care
arm (73% vs 44%; p= 0.075). Clinical implementation of symptom trig-
gered testing in theUK found thatwhilemorewomenwith ovarian can-
cer accessed expedited care pathways (two-week urgent referral), there
was no stage shift [8]. This was in keeping with retrospective studies
that reported no difference in stage or survival associated with time to
diagnosis in a population cohort of ovarian cancer patients diagnosed
in Australia [9] or with two-week urgent referral in an English
hospital-based cohort [10].
We are not aware of any studies in women with ovarian cancer that
explore the association of symptoms and routes to diagnosis with long
term survival adjusted for prognostic factors. Data from the population
cohort of women presenting clinically with invasive epithelial tubo-
ovarian cancer [11] (iEOC) in the ‘no screening’ (control) arm of the
UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) provides
an opportunity to explore this issue in more depth. We report on asso-
ciation of symptoms, intervals and routes to diagnosis with survival ad-
justed for prognostic factors.
2. Materials and methods
UKCTOCS is a randomised controlled trial assessing the impact of
population screening on ovarian cancer mortality [12,13]. In brief, fol-
lowing random invitation from population registers between 2001
and 2005, 202,638 postmenopausal women aged ≥50–74 years, were
recruited through 13 regional centres in England, Wales and Northern
Ireland. They were randomised to no screening (Control group –
101,359) or annual screening using a multimodal (MMS 50,640) or ul-
trasound (USS, 50,639) strategy. The cohort only included women
with at least one ovary, no significant family history of ovarian cancer
and no personal history of ovarian cancer or an active non-ovarian
malignancy.
2.1. Follow-up and confirmation of diagnosis
Participants were followed up via electronic health record linkage to
national cancer and death registrations (England and Wales - NHS dig-
ital; Northern Ireland-Health and Social Care Business Services Organi-
sation and Northern Ireland Cancer Registry). Additional sources
included two rounds of postal questionnaires (3–5 years after
randomisation and in 2014) and direct communication from, A. Gentry-Maharaj, et al., Ov
Oncology, https://doi.org/10.1participants. For women based in England, data was also obtained
from the National Cancer Intelligence Network (April 2001–March
2010) and Hospital Episode Statistics administrative records. Censor-
ship date for this analysis was 31st Dec 2014.
As previously detailed [13,14], medical notes were retrieved for all
women with notifications of a possible ovarian cancer diagnosis. An in-
dependent outcomes review committee assigned the final diagnosis
[15], date of diagnosis, FIGO 2003 stage, morphological Type [16]
(Type I- low-grade serous, low-grade endometrioid, clear cell, mucin-
ous, Type II - mainly high-grade serous carcinoma eTable 1), and
cause of death (where applicable).2.2. Subjects
All women with confirmed diagnosis as per WHO 2014 of primary
invasive epithelial tubo-ovarian cancer (includes tubal/peritoneal -
ICD-10 C57·0, C48·1, C48·2 in addition to C56.0) on outcomes review
were included in the analysis [17]. Women with borderline and non-
epithelial ovarian cancer were excluded.2.3. Symptom ascertainment
Symptom data was retrieved by hand searching of medical records,
which included copies of GP and hospital letters, multidisciplinary
team (MDT) summaries, hospital notes as well as trial records. All
symptoms were captured unless notes review confirmed they were
longstanding which was defined as N12months. Any accompanying di-
agnoses (e.g. joint pain with diagnosis of osteoarthritis) were noted. No
limit was placed on the number of symptoms that could be recorded for
each woman.
Women were classified as ‘symptomatic’ if they had presented
with any symptoms or ‘asymptomatic’ if this was documented or
no symptoms were mentioned despite the availability of compre-
hensive documentation. Women with ‘insufficient’ documentation
were classified as having missing data. The symptoms were grouped
as National Institute for Health and Care Excellence (NICE) UK guid-
ance [4] - positive (abdominal or pelvic pain, increased abdominal
size or bloating, loss of appetite/feeling full and increased urinary ur-
gency or frequency) or modified Goff Symptom index positive (ab-
dominal or pelvic pain, increased abdominal size or bloating and
loss of appetite/feeling full). The Goff symptom index includes dura-
tion and frequency of symptoms. The latter was not included in our
analysis as frequency was often not captured in the hospital notes.
Symptoms were also grouped according to system (gynaecological,
abdominal, gastrointestinal, urinary, systemic, other) as described
previously [18]. Symptoms not previously described were allocated
to the most appropriate system upon agreement of two clinical re-
searchers (JD and UM) (eTable 2).
Symptom interval was calculated from onset to date of diagnosis.
Date of onset was derived using GP and secondary care records.
Wherewomenhadmultiple episodes rather than a persistent symptom,
the start date of the first episode was recorded as date of onset. When
only the month was available, the midpoint (15th) was used. Diagnosis
was based on histological confirmation with the date used that of pri-
mary surgery or biopsy. In cases with no surgery or biopsy, the date cy-
tologywas takenwas used.Where none of thesewere available the date
confirmatory imaging was used.arian cancer symptoms, routes to diagnosis and survival – Population
016/j.ygyno.2020.05.002
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The date the woman was first seen in hospital, the speciality in-
volved and the route to that appointment was recorded. For those resi-
dents in England, thiswas supplementedwheremissing, with HES data.
The routes were classified as
1) emergency presentation (via accident and emergency department)
2) two-week urgent ‘cancer’ referral to rapid access outpatient diag-
nostic clinic
3) routine referral to secondary care (e.g. gynaecology or colorectal
outpatient clinic). The patients who were seen privately (outside
the NHS) were included in this group.
In women who had multiple appointments prior to diagnosis, the
first was taken as their route to diagnosis.
2.5. Primary treatment and surgical outcome
The medical notes especially the surgical records and details of che-
motherapy received were used to classify women into primary treat-
ment categories (eTable 1). In patients who underwent surgery
whether primary or interval debulking, the amount of residual disease
as recorded by the surgeon in the operation record was extracted.
2.6. Statistical analysis
Standard survivalmethodswere used to analyse the data,with entry
fixed at date of diagnosis, exit at date of death from ovarian cancer, or
date of censorship (loss to follow-up or 31st December 2014). Cox
models were used to obtain hazard ratio estimates of variables. Formal
tests of the proportional hazards assumption were performed using
the Schoenfeld residuals.
Survival curves were based on the Kaplan-Meier (KM) estimator.
However, a distinction is to be made between analyses considering
A) mutually exclusive variables – (1) women presenting with
symptoms listed or not on themodifiedGoff Index (2) symptoms
listed or not in the NICE guidelines (2) (3) route to diagnosis,
(4) speciality, (5) cancer type, (6) primary treatment (7) residual
disease following surgery, and (8) number of symptoms where
KM curves were individually estimated for each variable. KM
curves for number of symptoms, were based on the Cox model
as this was modelled continuously with fractional polynomials.
B) variables that were not mutually exclusive – (9) individual mod-
ified Goff symptoms, (10) symptoms grouped by system where
the survival curves based on the Cox model result, resulting in
‘proportional’ curves by design. Here the baseline was implied
where all indicator variables were zero.
A multivariable model was fitted for individual symptoms, time in-
terval from symptom onset to diagnosis, route to diagnosis, speciality,
Type, age at diagnosis, year of diagnosis (period effect), BMI, stage, pri-
mary treatment, and residual disease. To look at period effects, the year
of diagnosis was categorised with 2010 as the reference, as this was the
year prior to the introduction of NICE guidelines in UK. To address the
issue of missing data, we performed a multiple imputation (MI) using
chained equations (MICE) to preserve as much information as possible
and provide correct inference for the multivariable Cox model. The
three modified Goff symptom variables were imputed using a logit
model, time from symptom to diagnosis using a linear regression
model after first log transforming, stage using an ordered logit model,
and route to diagnosis and speciality using a multinomial logit model.
20 fully imputed datasets were created using MICE and following
model fitting on all 20 sets, parameter estimates with standard errors
were calculated using Rubin's rules [19].Please cite this article as: J. Dilley, M. Burnell, A. Gentry-Maharaj, et al., Ov
cohort study in the ‘no scree..., Gynecologic Oncology, https://doi.org/10.12.7. Literature review
We searched the Cochrane Library (2010–2017), MEDLINE (1947 to
week 372,017), and EMBASE (1947 to week 372,017) using the terms
MESH “ovarian cancer” in combination with the terms “symptoms” or
“routes to diagnosis”. We selected publications in the past 5 years, but
did not exclude commonly referenced and highly regarded older publi-
cations (eTable 3).
3. Results
Between randomisation (2001–5) and 31st December 2014, 645 of
the 101,299 women were diagnosed with primary tubo-ovarian can-
cer). This included 574 iEOC, 62 borderline epithelial and 8 non-
epithelial cancers. Histology was not available for one woman. This
analysis was restricted to the 574 with iEOC. The cohort consists of
mainly white (97.9%) women,median age of 62·7 years at recruitment.
8·2% had a personal history of cancer and 2·1% a maternal history of
ovarian cancer (eTable 4).
23·9% (137/574) had early (I and II) and 75·9% (436/574) advanced
(III and IV) stage disease. The majority (73·9%; 424/574) were Type II,
which represents mainly high grade serous cancer. Forty eight per
cent (280/547) underwent primary surgery and adjuvant chemother-
apy, 19% (110/547) neoadjuvant chemotherapy and interval debulking
and 19% only chemotherapy. Complete resection of all disease, leaving
no residual disease was recorded as being achieved in 31·5% (181/
574) (eTable 1).
90.8% (521/574) reported symptoms (Table 1), most commonly ab-
dominal or pelvic pain (39·5%, 227/574) or increased abdominal size or
bloating (39.2%, 225/574). One in five (20%, 115/574) reported change
in bowel habit. There were 29 additional symptoms to the ten listed in
Table 1, which were reported by 29.8% (171/574) of women. 2.3%
(13/574) of women reported no symptoms prior to diagnosis. In 6.9%
(40/574) data was insufficient to determine if symptomatic or asymp-
tomatic. In the remaining, number of symptoms ranged from 1 to 9
(median 2).
Grouping symptoms into systems revealed that 65% (375/574) of
women had abdominal symptoms (Table 1). Two thirds of women
were positive for NICE symptoms (66%; 381/574) with a slightly lower
proportion for modified Goff symptoms (63%; 362/574).
The commonest route to diagnosis was via two-week urgent cancer
referral (37%, 214/574) with the majority (85.5%, 183/213) being made
to gynaecology. A similar proportion ofwomenwere referred by routine
referral (32%, 185/574) and a quarter 24% (137/574) presented as an
emergency (eTable 5).
The median interval from symptom onset to diagnosis in 316
women for whom data was available was 80 days (IQR 83). There was
a trend to shorter median intervals in women diagnosed with Type II
(78 days; IQR 82·5) and uncertain Type (66·5 days; IQR 86) (Table 1).
Overall one and five-year survival in this cohortwas 76% and 33% re-
spectively, with those with Type I iEOC having significantly better sur-
vival than those with Type II or Type uncertain (eFig. 1A, eTable 6).
Significantly worse survival was seen in women presenting with NICE
(Fig. 1A) or modified Goff (Fig. 1B) symptoms compared to no such
symptoms (eTable 6). Therewas no significant difference in survival be-
tween women diagnosed with these symptoms prior to the introduc-
tion of NICE guidelines in UK in 2011 compared to 2012 onwards
(eFig. 1B, eTable 6). The women's risk of death increased by 20% with
each additional symptom beyond the first (eFig. 1C). Of the modified
Goff symptoms, abdominal pain and loss of appetite/feeling full were
associated with worse survival compared to the absence of those symp-
toms (Fig. 2A, eTable 6).
On univariant analysis when grouped by systems, women with gas-
trointestinal symptoms had worst survival and those with
gynaecological and urinary symptoms the best (Fig. 2B). Compared
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Fig. 1. Survival curves of women with invasive epithelial tubo-ovarian cancer in the ‘no screening’ arm of UKCTOCS, with presenting symptoms included in (A) NICE guidelines vs not










0 5 10 15
survival time in years
gnitaolbniaplanimodba
loss of appetite/feeling full non-GOFF symptoms










0 5 10 15
analysis time
abdominal GI gynae systemic
urinary other none
Cox proportional hazards regression(A)
(B)
Fig. 2. Survival curves of womenwith invasive epithelial tubo-ovarian cancer in the ‘no screening’ arm of UKCTOCS, (A)With the three individual symptoms that constitute themodified
Goff index (B) With symptoms affecting different systems*. *abdominal, GI, gynae, urinary, systemic, other and none.
Table 1
Presenting symptoms, interval to diagnosis and survival of women diagnosed with invasive epithelial tubo-ovarian cancer (iEOC).
Presenting symptoms/symptom complexes (only
symptoms with ≥10% women)












Type I and II
Symptoms
Abdominal or pelvic discomfort/pain 227 (39.5%) 26(29.5%) 170(40.1%) 30(48.4%) 0.055 0.058
Increased abdominal size/bloating 225 (39.2%) 22(25%) 167(39.4%) 35(56.5%) 0.001 0.023
Change in bowel habit 115 (20%) 11(12.5%) 88(20.8%) 15(24.2%) 0.133 0.068
Loss of appetite/feeling full 84 (14.6%) 7(8%) 62(14.6%) 15(24.2%) 0.022 0.096
Weight loss 67 (11.7%) 6(6.8%) 53(12.5%) 8(12.9%) 0.304 0.129
Lump or mass felt by woman 45 (7.8%) 12(13.6%) 29(6.8%) 4(6.5%) 0.089 0.033
Respiratory symptoms 44 (7.7%) 3(3.4%) 33(7.8%) 8(12.9%) 0.097 0.144
Vaginal bleeding 44 (7.7%) 11(12.5%) 30(7.1%) 3(4.8%) 0.167 0.106
Urinary frequency 39 (6.8%) 8(9.1%) 31(7.3%) 0(0%) 0.066 0.567
Nausea 29 (5.1%) 2(2.3%) 23(5.4%) 4(6.5%) 0.408 0.212
Other symptom 171 (29.8%) 25(28.4%) 126(29.7%) 20(32.3%)
Asymptomatic 13 (2.3%) 2(2.3%) 16(3.7%) 0(0%)
Missing data 40 (6.9%) 9(10.2%) 29(6.8%) 2(3.2%)
Abdominal 375 (65%) 51(58%) 277(65.3%) 47(7.6%)
Gastrointestinal 156 (27%) 18(20.5%) 118(27.8%) 20(32.3%)
Systemic 133 (23%) 11(12.5%) 101(23.8%) 21(33.9%)
Urinary 76 (13%) 13(14.8%) 61(14.4%) 2(3.2%)
Gynaecological 60 (10%) 12(13.6%) 45(10.6%) 3(4.8%)
Other 65 (11%) 7(8%) 49(11.6%) 9(14.5%)
Modified Goff 362 (63%) 47 (53.4%) 268 (63.2%) 47 (75.8%)
NICE 381 (66%) 53 (60.2%) 281 (66.3%) 47 (75.8%)
Overall Type I Type II Type uncertain
Interval from symptom onset to diagnosis in days- median (inter quartile)
No. of patients with symptoms 521 77 384 60
No. of patients with data on interval 316 46 232 38
Overall 80 (83) 93 (122) 78 (82.5) 66.5 (86)
Early Stage patients 91 (88.5) 92 (79) 88 (71) 146.5 (175)
Late Stage patients 75 (84) 98 (144) 76 (82) 66 (89)
One and five year survival
No. of patients 574 88 424 62
One year survival (IQR) 76% 93% 78% 42%
Five year survival (IQR) 33% 76% 29% 5%
One year survival early stage patients 94% 97% 91% 50%
Five year survival in early stage patients 79% 88% 70% 50%
One year survival in late stage patients 71% 78% 75% 41%
Five year survival in late stage patients 19% 28% 21% 3%
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Table 2
Hazard ratios for mortality in the multivariable imputation model.






0.78 0.28–2.21 0.643 0.415 −0.46
Modified Goff Symptoms (compared to absence of symptom)
Loss of appetite/Feeling full 1.43 1.04–1.96 0.026 0.229 2.23
Abdominal/Pelvic pain 1.34 1.05–1.72 0.018 0.168 2.37
Increase abdominal size/Bloating 1.12 0.85–1.48 0.411 0.158 0.82
NICE additional symptom in women who did not have the Modified Goff symptom
(compared to absence of that symptom)
Urinary urgency/frequency 1.18 0.59–2.38 0.637 0.421 0.47
Age 1.01 0.99–1.03 0.241 0.010 1.17
BMI 1.00 0.97–1.02 0.888 0.012 −0.14
Initial specialist seen in secondary care (compared to Emergency department)
Overall p value for variable 0.648
Emergency department 1.00
Gynaecology 0.80 0.48–1.33 0.386 0.208 −0.87
Gastrointestinal 0.87 0.55–1.40 0.568 0.209 −0.57
Other 0.73 0.42–1.29 0.279 0.211 −1.08
Route to diagnosis (compared to two-week urgent cancer)
Overall p value for variable 0.780
Two-week urgent cancer 1.00
Routine 1.02 0.76–1.37 0.892 0.152 0.14
Emergency 1.12 0.79–1.59 0.506 0.199 0.66
Time symptoms to diagnosis 0.95 0.79–1.14 0.589 0.087 −0.54
Stage (compared to Stage 1)
Overall p value for variable b0.001
1 1.00
2 1.36 0.63–2.92 0.432 0.531 0.79
3 3.27 1.75–6.11 b0.001 1.043 3.71
4 2.66 1.37–5.15 0.004 0.897 2.89
Type (compared to Type I)
Overall p value for variable 0.326
I 1.00
II 1.18 0.69–2.03 0.55 0.327 0.6
Uncertain 1.50 0.80–2.81 0.209 0.482 1.26
Year (compared to 2010a)
Overall p value for variable 0.063
2010 1.00
2002 1.52 0.51–4.51 0.453 0.843 0.75
2003 1.57 0.66–3.75 0.312 0.697 1.01
2004 1.68 0.93–3.03 0.087 0.505 1.71
2005 1.49 0.87–2.57 0.149 0.414 1.44
2006 1.51 0.92–2.49 0.105 0.384 1.62
2007 0.71 0.41–1.22 0.209 0.196 −1.26
2008 1.02 0.63–1.63 0.948 0.244 0.07
2009 1.00 0.61–1.63 0.997 0.250 0
2011 1.05 0.62–1.78 0.846 0.281 0.19
2012 1.26 0.75–2.13 0.383 0.336 0.87
2013 1.27 0.72–2.25 0.413 0.370 0.82
2014 2.39 1.12–5.10 0.024 0.924 2.26
Surgery- residual disease (compared to 0 mm)
Overall p value for variable b0.001
Zero 1.00
N0 mm and ≤10 mm 1.58 1.05–2.37 0.027 0.328 2.21
N10 mm and ≤20 mm 2.67 1.71–4.16 b0.001 0.604 4.34
N20 mm or no surgery 2.03 0.91–4.50 0.083 0.825 1.73
Primary treatment (compared to Neo adjuvant chemotherapy and interval debulking
surgery)
Overall p value for variable b0.001
Neo adjuvant chemotherapy and
interval debulking surgery
1.00
Primary surgery plus adjuvant
chemotherapy where appropriate
0.66 0.47–0.91 0.012 0.110 −2.5
Primary chemotherapy 1.91 0.89–4.12 0.097 0.749 1.66
No treatment with curative intent 5.99 2.69–13.35 b0.001 2.448 4.38
Primary surgery and no adjuvant
chemotherapy although
recommended
12.41 6.33–24.34 b0.001 4.265 7.33
a Includes Stage I patients where chemotherapy was not recommended.
5J. Dilley et al. / Gynecologic Oncology xxx (2020) xxxpresenting as an emergency had significantly worse survival (eFig. 1D,
eTable 6). Irrespective of route to diagnosis, compared to women ini-
tiallymanaged by a gynaecologist, those initially managed by the emer-
gency physicians or gastrointestinal physicians/surgeons had worse
survival (eFig. 1E).
The multivariable analysis involves 573 patients – one women had
no treatment data and was excluded. In addition to advanced stage, in-
adequate primary treatment and increasing residual disease, abdominal
pain, loss of appetite/feeling full, were significantly associated with in-
creased mortality (Table 2).
4. Discussion
In this population cohort study of postmenopausal women with in-
vasive epithelial ovarian/tubal/peritoneal cancer, those with symptoms
listed on the NICE guidelines or modified Goff Index had significantly
worse survival compared to those who did not. Abdominal pain and
loss of appetite/feeling full was significantly associated with increased
mortality on multivariate analysis alongside advanced stage, increasing
residual disease and inadequate primary treatment. It needs to be noted
however, that this study cannot exclude the possibility that within the
group of symptomatic women who collectively have a poor outcome,
those who act early on their symptoms may have a better outcome
than those who do not.
4.1. Strength and weakness
The focus is on invasive epithelial cancer,which is themajor contrib-
utor tomortality in this disease. The key strength is that selection bias is
minimised as significant efforts were made via linkage to multiple na-
tional registries and postal follow-up to ensure all those with the dis-
ease were identified. Site, stage and Type were confirmed by
independent outcome review. Similar incidence and survival of ovarian
cancer in this group compared to the UK age matched population [14]
ensures that the cohort is representative and the findings therefore
generalisable. Symptom data were collected using both primary and
secondary care records. To allow comparison, similar rules as reported
in the literature [18], were used to group symptoms by system. Al-
though symptom data was collected prior to any diagnosis of ovarian
cancer, the retrospective review of records is a weakness. Consequently
the collection of symptomdata is different from theGoff index that uses
prospective questionnaire to screen women for symptoms of ovarian
cancer. However, previous work [20] has suggested questionnaires
and medical records have comparable specificity. The NICE symptom
index relies on women presenting to healthcare professionals and
volunteering symptoms, a method, which is more closely aligned to
that used in this study. The Goff symptoms index uses both duration
and frequency in the evaluation process. Though data was collected
for duration of symptoms, it wasmissing in 45% (258/574).Multiple im-
putation was undertaken using MICE to preserve as much information
as possible and provide correct inference. It was not possible to deter-
mine the frequency nor severity of symptoms. A further potentialweak-
ness is that the model does not include performance status or medical
comorbidity, both of which could be confounders when interpreting
certain symptoms and in survival.
4.2. Findings in the context of literature
Since the publication of the Goff symptom index [3], symptom
awareness has been promoted as an approach that would enable earlier
diagnosis of ovarian cancer and has been incorporated into national
guidelines such as NICE [4]. Our findings of worse survival in women
with NICE or modified Goff symptoms are in keeping with reports that
these symptoms are more likely in women with advanced disease [21].
The incidence of common symptoms reported in our study (abdom-
inal/pelvic discomfort or pain, increased abdominal size or bloating andPlease cite this article as: J. Dilley, M. Burnell, A. Gentry-Maharaj, et al., Ovarian cancer symptoms, routes to diagnosis and survival – Population
cohort study in the ‘no scree..., Gynecologic Oncology, https://doi.org/10.1016/j.ygyno.2020.05.002
6 J. Dilley et al. / Gynecologic Oncology xxx (2020) xxxchange in bowel habit) closely matches that in similar studies [22–24].
As previously reported [22], increasing number of symptoms led to a
worsening of survival. This is a reflection of increasing disease burden,
which increases the clinical complexity, adding to the diagnostic
challenge.
Our findings that emergency presentation confers worse survival
compared with two-week urgent ‘cancer’ referral are in line with Bar-
clay et al. [25] and Altman et al. [26]. It highlights the need to ensure
for fast tracking of referrals to gynaecological services. However, the
time interval between initial onset of symptoms and diagnosis did not
independently influence survival once other factors such as age, stage
and Type were included in the analysis. This aligns with Nagle et al.
[9] who found that in symptomatic ovarian cancer reducing time to di-
agnosis does not alter stage or survival. Although reducing the time to
diagnosis is associated with more favourable outcomes in breast, colo-
rectal, head and neck, melanoma and testicular cancers [27], the benefit
varies between cancers. The lack of benefit in iEOC is probably a reflec-
tion of disease biology. Across all stages, larger volumes of residual dis-
ease led to a significantly worse survival, which is in keeping with
current surgical philosophy ofmaximal surgical effort to removal all dis-
ease [26,28,29].
The introduction of the NICE guidelines did not improve survival in
our study. A recent UK based study [8] found thatwhile the introduction
of the NICE guidelines did increase in number of case of ovarian cancer
being diagnosed, it did not result in a shift in stage at diagnosis.
4.3. Implications
There are two important implications of the findings of this
population-based study. The first that the symptom complexes identify
womenwith a poorer prognosis. While it is necessary to continue mea-
sures to ensure prompt referral and reduce emergency presentations, it
is difficult to assess the impact of thesemeasures on overall survival. To
decrease deaths from ovarian cancer, it is critical we remain focussed on
understanding disease biology, exploring preventative strategies, refin-
ing the current screening strategies by incorporating novel tests and
optimising surgical and adjuvant treatment.
The second that the evidence cannot exclude the possibility of better
outcomes in thosewho are aware and act on these symptoms compared
to those who do not. A worse survival in women with more symptoms
would support this. Definitive proof of this requires further randomised
controlled trials like DOvE. Meanwhile, women should be encouraged
to seek help as longer intervals to diagnosis and treatment are associ-
ated with reduced overall quality of life and decreased patient
satisfaction [30].
5. Conclusions
Symptoms awareness using the NICE Guidance 2011 and modified
Goff Index and other similar [5,31] guidance has been widely adopted
as amethod to identify ovarian cancer earlier.Womenwith these symp-
tom complexes are likely to have advanced disease and poorer survival.
The lack of significant impact on survival of healthcare interventions
such as route or interval to diagnosis or secondary care team involved
in initial management suggests that in invasive epithelial tubo-ovarian
cancer, tumour biology is the overriding driver of survival.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2020.05.002.
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